Friday, 20 November 2026European Markets

ABIVAX Stock Was Up By 14.16% Today

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Loading stream...

(vianews) - the market ended the session with abivax (abvx.pa) rising 14.16% to €9.19 on thursday while cac 40 rose 0.12% to €7,324.75.

abivax's last close was €8.05, 68.43% under its 52-week high of €25.50.

about abivax

abivax société anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in france. its principal products include abx464 that is in phase iib clinical trials for the treatment of ulcerative colitis and crohn's disease, as well as for covid-19; phase iia clinical trial for the treatment of rheumatoid arthritis diseases; and has completed phase iia clinical trial for the treatment of viral remission in patients with hiv. it also develops abx 196, an immune enhancer candidate that is in phase 1/2 clinical trials for the treatment of hepatocellular cancer. in addition, the company engages in the research programs for the treatment of dengue fever, influenza, and respiratory syncytial virus. abivax société anonyme has license contracts with the french national centre for scientific research, the university of montpellier, and the institut curie. the company was incorporated in 2013 and is headquartered in paris, france.

earnings per share

as for profitability, abivax has a trailing twelve months eps of €-2.53.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -1286.47%.

volume

today's last reported volume for abivax is 102825 which is 428.06% above its average volume of 19472.

yearly top and bottom value

abivax's stock is valued at €9.19 at 22:30 est, way under its 52-week high of €25.50 and way above its 52-week low of €5.60.

volatility

abivax's last week, last month's, and last quarter's current intraday variation average was 5.14%, 1.26%, and 2.14%.

abivax's highest amplitude of average volatility was 5.14% (last week), 2.76% (last month), and 2.14% (last quarter).

moving average

abivax's value is way higher than its 50-day moving average of €6.67 and way above its 200-day moving average of €7.71.

more news about abivax (abvx.pa).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 6 Apr 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›